Having a biochemical test,based on quantification of a specific DLB biomarker within Cerebrospinal Fluid(CSF) could be an effective diagnostic method to improve the differential diagnosis.Although some of the investigated DLB CSF biomarkers are well within theclinical criteria for sensitivity and specificity (>90%), they all seem to be confoundedby the contradictory data for each of the major groups of biomarkers (α-synuclein, tauand amyloid proteins). The gene discussed is SNCA; the disease is Lewy body dementia.